Background Consistent with fulminant endothelial cell activation, elevated plasma von
Willebrand factor (VWF) antigen levels have been reported in patients with COVID‐19. The …

OBJECTIVES: Prevention and therapy of immunothrombosis remain crucial challenges in
the management of coronavirus disease 2019, since the underlying mechanisms are …

Acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder that may cause life-threatening
hemorrhages in patients with plasma cell dyscrasias (PCDs). Early diagnosis and …

Ubiquitous microthromboses in the pulmonary vasculature play a crucial role in the
pathogenesis of COVID-19 associated acute respiratory distress syndrome (ARDS). Excess of …

Background Quantifying A disintegrin‐like and metalloprotease with thrombospondin type 1
motif, member 13 (ADAMTS‐13) activity enhances thrombotic thrombocytopenic purpura (…

It has recently been shown that von Willebrand factor (VWF) multimers contribute to
immunothrombosis in Coronavirus disease 2019 (COVID-19). Since COVID-19 is associated with an …

Background Data are lacking on the relative incidence of thrombotic thrombocytopenic
purpura (TTP), haemolytic uraemic syndrome (HUS) caused by Shiga toxin–producing …

Acquired von Willebrand syndrome (aVWS) accounts for 22% of patients with abnormal von
Willebrand factor. Most patients with known pathophysiological mechanisms suffer from …

Background Thrombotic microangiopathy (TMA) has been repeatedly described in COVID-19
and may contribute to SARS-CoV-2 associated hypercoagulability. The underlying …

Acquired hemophilia A (AHA) and acquired von Willebrand Syndrome (AVWS) are both rare
bleeding disorders that can be associated with lymphoproliferative or autoimmune diseases…